The EU has pledged €30m in funding for countermeasures to antimicrobial resistance, earmarked for the discovery and development of new antibacterials.

Insmed has given up on Brinsupri in the painful skin disorder hidradenitis suppurativa (HS) after a mid-stage trial failure. The company had ditched the pill

A bid to limit access to the abortion pill mifepristone in the US, while the FDA carries out a review of the drug, has been

A dozen or so European drug development startups might soon get a major lift from Jeito Capital. The Paris-based firm closed its second fund at

Eli Lilly may not have discovered orexins, but the pharma’s latest acquisition marks increasing momentum for a drug class that’s maturing after years of fine-tuning.